Plain-English translation of NCT07145801 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a special type of ultrasound imaging—called contrast-enhanced ultrasound (CEUS)—can help doctors better understand how well radioembolization treatment is working for liver cancer. The study uses two different contrast dyes, Lumason and Sonazoid, which are injected into your bloodstream during the ultrasound to highlight how blood flows through your tumor. The goal is to see if this imaging method can give doctors clearer information about treatment response compared to the CT or MRI scans you'd normally receive.
Currently, doctors rely mainly on CT and MRI scans to check if radioembolization treatment is working, but these scans don't always show the full picture of what's happening in the tumor. This study is exploring whether contrast-enhanced ultrasound might provide additional or clearer information to help guide treatment decisions and detect whether cancer is responding as expected.
You likely qualify if…
You likely don't qualify if…
After you receive radioembolization treatment, you'll come back for ultrasound imaging appointments at about 1–2 months and 4–6 months afterward. During each visit, a technician will inject contrast dye into your vein while performing an ultrasound to watch how the dye moves through your tumor and liver over several minutes. The entire ultrasound exam takes about 30–60 minutes, and you'll be monitored for at least 30 minutes after the exam before you leave. If your doctor decides you need additional treatment before the 4–6 month mark, you may have an additional ultrasound scan at that time.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States